Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15962 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Dror Dicker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department D and Obesity Clinic, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Bariatric Surgery, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Metformin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Ariel University.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate the association of metformin continuation with relapse of diabetes after metabolic bariatric surgery (MBS) in patients with type 2 diabetes and obesity who achieved an HbA1c level of less than 6.5%. Materials and Methods This observational, retrospective cohort study included Clalit Health Service members aged 24 years or older with obesity and diabetes, who were treated with metformin, underwent MBS during 2005‐2020 and achieved an HbA1c level of less than 6.5% up to 6 months after surgery (index date). Patients who continued metformin treatment (> 2 prescriptions filled, n = 122) after the index date were matched (1:2) on age, sex and HbA1c level at index date and compared with those who stopped treatment (no filled prescriptions, n = 244). The outcome was relapse of diabetes as measured by an HbA1c level of 6.5% or higher (yes/no).
Results
The two matched groups maintained a mean HbA1c level of less than 6.5% during the follow‐up (mean ~ 5 years). An adjusted Cox proportional hazards model revealed no significant association of metformin continuation after MBS with relapse of diabetes (adjusted hazard ratio = 1.70, 95% confidence interval: 0.98‐2.94). No significant differences were observed between the two groups in weight loss and filled prescriptions for other diabetes medications during the follow‐up period.
Conclusions
Among individuals living with obesity and diabetes who achieved diabetes remission post‐MBS, metformin continuation was not associated with relapse of diabetes. This lack of an association indicates that metformin did not provide an additional benefit for maintaining glycaemic control or weight reduction during an average of 5 years postsurgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Department D and Obesity Clinic, Hasharon Hospital, Rabin Medical Center, Petah Tikva, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Health Systems Management, Ariel University, Ariel, Israel.
ORCID-Profile: Dror Dicker, Orna Reges
Förderung
- Ariel University
Zitieren
APA
Dicker, D., Pinto, D., & Reges, O. (2024). Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15962
Vancouver
Dicker D, Pinto D, Reges O. Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15962
BibTeX
@article{Dicker2024,
author = {Dicker, Dror and Pinto, Danna and Reges, Orna},
title = {Metformin continuation post‐metabolic bariatric surgery and relapse of diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15962}
}
EUVIMED